Since February 2016, we’ve followed the testy merger between Abbott (NYSE: ABT) and Alere’s (NYSE: ALR) agreement to merge, followed by the respective lawsuits, and then the price renegotiation. Half way through 2017, the $5.3 billion deal is getting closer to completion, as Alere spins off some assets to comply with antitrust regulations.
More than a year after Abbott and Alere agreed to merge, the lawsuits have been closed and the marriage is back on. The contract was renegotiated, of course.
The party’s about over for the $5.8 billion Abbott (NYSE: ABT) acquisition of Alere Inc. (NYSE: ALR). Everything was bright and rosy when Abbott agreed to pay $56.00 per share for the point-of-care diagnostics and services company. Now, the $177 million termination fee Abbott faces to get out of the deal looks pretty cheap. In April, Abbott reportedly […]
It’s been a busy year for healthcare deal making. As of December 2, the combined total spending was $239.1 billion, going to finance 1,419 transactions. That’s 40% behind the $400 billion spent in all of 2015, but just 7% behind last year’s deal volume of 1,520 deals.
It’s been a busy year for mergers and acquisitions in the Medical Device sector. Through December 2, 108 transactions have been announced in 2016, compared with 113 in all of 2015. Target companies specializing in cardiovascular devices make up a small percentage of those deals, but tend to post large prices. So far, $32.8 billion […]
Only a few weeks into the fourth quarter, and five medical device deals have been announced, putting the year’s total at 95. Abbott (NYSE: ABT) and St. Jude Medical’s (NYSE: STJ) $1.12 divestiture of certain vascular closure and electrophysiology assets is among these five October deals, and the only one to disclose a price. On October […]
You’ve seen the headlines: Global mergers and acquisitions slid in the first half of 2016, as did the combined value. The number of middle market deals completed in the second quarter fell to levels not seen since 2009. Buyers are walking away from targets that could be affected by sudden changes in tax regulations. It’s […]
We’re still in preliminary territory, so don’t bank on this yet. Health care M&A hit 120 deals for the month of April 2016, down 12% versus the previous month’s 136 deals, but 7% better than the same month a year ago. Long-term care deals led the transaction activity with 21 deals (18% of the total), […]
Medical device deals are back in fashion. In the first four months of 2016, 41 deals were announced in this sector, compared with just 30 for the comparable time period in 2015. Spending on deals in this sector has already hit $42.7 billion, compared with $5.7 billion in the first four months of 2015. The largest by far this […]